Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.

ABSTRACT: In patients with chronic lymphocytic leukemia, Richter transformation (RT) reflects the development of an aggressive lymphoma that is associated with poor response to chemotherapy and short survival. We initiated an international, investigator-initiated, prospective, open-label phase 2 study in which patients with RT received a combination of the PD-1 inhibitor tislelizumab plus the BTK inhibitor zanubrutinib for 12 cycles. Patients responding to treatment underwent maintenance treatment with both agents. The primary end point was overall response rate after six cycles. Of 59 enrolled patients, 48 patients received at least two cycles of treatment and comprised the analysis population according to the study protocol. The median observation time was 13.9 months, the median age was 67 (range

SUBMITTER: Al-Sawaf O 

PROVIDER: S-EPMC10803258 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature